共 50 条
- [41] A phase I trial of the γ-secretase inhibitor (GSI) MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma (PDAC).JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Cook, NatalieBasu, BristiSmith, Donna-MichelleGopinathan, AarthiEvans, Thomas JeffSteward, William P.Hagemann, ThorstenVenugopal, BalajiTuveson, David A.Hategan, MirelaAnthoney, David AlanFarmer, HayleyTurner, HelenMcLeod, RobertHalford, Sarah E. R.Jodrell, Duncan Ian
- [42] Randomized phase 2 trial of peri- or post-operative chemotherapy in resectable pancreatic adenocarcinomaANNALS OF ONCOLOGY, 2017, 28Reni, M.Zanon, S.Balzano, G.Castoldi, R.Zerbi, A.Tronconi, M. C.Pinelli, D.Mosconi, S.Doglioni, C.Falconi, M.Gianni, L.
- [43] A phase II study of abemaciclib as a monotherapy and in combination with other agents in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Chiorean, E. GabrielaHochster, Howard S.Nanda, ShivaniThornton, DonaldKlise, Suzanne
- [44] A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal AdenocarcinomaANNALS OF SURGERY, 2018, 268 (04) : 610 - 619Tsai, SusanChristians, Kathleen K.George, BenRitch, Paul S.Dua, KulwinderKhan, AbdulMackinnon, A. CraigTolat, ParagAhmad, Syed A.Hall, William A.Erickson, Beth A.Evans, Douglas B.
- [45] A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinomaJOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, : 3216 - 3226Aung, Kyaw L.McWhirter, ElaineWelch, StephenWang, LisaLovell, SophiaStayner, Lee-AnneAli, SaaraMalpage, AnneMakepeace, BarbaraRamachandran, MakilpriyaJang, Gun HoGallinger, StevenZhang, TongStockley, Tracy L.Fischer, Sandra E.Dhani, NeeshaHedley, DavidKnox, Jennifer J.Siu, Lillian L.Goodwin, RachelBedard, Philippe L.
- [46] Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II TrialJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (32)Ludmir, Ethan B.Sherry, Alexander D.Fellman, Bryan M.Liu, SuyuBathala, TharakeswaraHaymaker, CaraMedina-Rosales, Marina N.Reuben, AlexandreHolliday, Emma B.Smith, Grace L.Noticewala, Sonal S.Nicholas, SarahPrice, Tracy R.Martin-Paulpeter, Rachael M.Perles, Luis A.Lee, Sunyoung S.Lee, Michael S.Smaglo, Brandon G.Huey, Ryan W.Willis, JasonZhao, DanCohen, LorenzoTaniguchi, Cullen M.Koay, Eugene J.Katz, Matthew H. G.Wolff, Robert A.Das, PrajnanPant, ShubhamKoong, Albert C.Tang, Chad
- [47] A phase 1 trial of combined MEK, STAT3 and PD-1 inhibition in metastatic pancreatic ductal adenocarcinoma (PDAC).JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS713 - TPS713Hosein, Peter JoelDatta, JashodeepEzenwajiaku, NkirukaZhou, ZhiqunYow, Maria V.Boone, MelindaNagathihalli, NagarajReis, Isildinha M.Merchant, Nipun B.
- [48] Preliminary safety data from a randomized multicenter phase Ib/II study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Katz, Matthew H. G.Varadhachary, Gauri R.Bauer, Todd W.Acquavella, NicolasMerchant, Nipun B.Le, Tri MinhJavle, Milind M.
- [49] FOLFIRINOX plus high intensity focused ultrasound for locally advanced/borderline resectable pancreatic ductal adenocarcinoma: A prospective single arm phase II trial.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 670 - 670Lee, Dong HoLee, Jae YoungLee, Sang HyubJang, Jin-Young
- [50] A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic AdenocarcinomaANNALS OF SURGICAL ONCOLOGY, 2023, 30 (02) : 688 - 690Saif, AreebaVerbus, EmilyErickson, BethKamgar, MandanaTsai, SusanEvans, DouglasHernandez, Jonathan M.Hall, William A.